Want to see IN:SURAKSHA full AI Analyst Report?
SURAKSHA Stock Chart & Stats
₹300.85
-₹13.40(-3.48%)
At close: 4:00 PM EST
₹300.85
-₹13.40(-3.48%)
Day’s Range― - ―
52-Week Range₹224.10 - ₹333.65
Previous CloseN/A
Volume140.52K
Average Volume (3M)1.23K
Market Cap
₹16.86B
Enterprise Value₹16.27K
Total Cash (Recent Filing)₹263.48M
Total Debt (Recent Filing)₹1.30B
Price to Earnings (P/E)46.2
Beta1.01
Next Earnings
Dec 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)6.18
Shares Outstanding52,080,757
10 Day Avg. Volume1,073
30 Day Avg. Volume1,225
Financial Highlights & Ratios
PEG Ratio32.20
Price to Book (P/B)4.85
Price to Sales (P/S)3.82
P/FCF Ratio70.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)9.2
Revenue Forecast (FY)₹3.68B
Bulls Say, Bears Say
Bulls Say
Sustained Revenue GrowthRevenue growth has remained strong for three consecutive years after the FY23 contraction. This indicates improving demand and business scale, creating a durable foundation for operating leverage and continued expansion over the next several quarters.
Healthy Operating ProfitabilityHealthy operating and EBITDA margins show that the business can generate meaningful profitability as revenue expands. This provides resilience against moderate cost pressure and supports reinvestment in facilities, services, and future growth.
Positive Operating Cash GenerationOperating cash flow exceeding accounting profit supports earnings quality and indicates that core operations are converting reported results into cash. This strengthens internal funding capacity, even though free-cash-flow conversion remains constrained.
Bears Say
Margin VolatilityThe sharp deterioration in gross margin and lower net margin point to possible pricing pressure, cost inflation, or adverse service mix. If persistent, this could limit operating leverage and make future earnings less predictable.
Rising Leverage And Lower ReturnsDebt has increased since FY25 while returns on equity have softened, reducing financial flexibility relative to the prior year. Although leverage remains manageable, continued borrowing without stronger returns could constrain investment capacity.
Weak Free-Cash-Flow ConversionLow and uneven free-cash-flow conversion suggests that capital expenditure or working-capital requirements absorb much of the cash generated by operations. This can limit funding for expansion and increase reliance on debt or external capital.
Suraksha Diagnostic Ltd. News
SURAKSHA FAQ
What was Suraksha Diagnostic Ltd.’s price range in the past 12 months?
Suraksha Diagnostic Ltd. lowest stock price was ₹224.10 and its highest was ₹333.65 in the past 12 months.
What is Suraksha Diagnostic Ltd.’s market cap?
Suraksha Diagnostic Ltd.’s market cap is ₹16.86B.
When is Suraksha Diagnostic Ltd.’s upcoming earnings report date?
Suraksha Diagnostic Ltd.’s upcoming earnings report date is Dec 18, 2026 which is in 114 days.
How were Suraksha Diagnostic Ltd.’s earnings last quarter?
Suraksha Diagnostic Ltd. released its earnings results on Aug 12, 2026. The company reported ₹2.5 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Suraksha Diagnostic Ltd. overvalued?
According to Wall Street analysts Suraksha Diagnostic Ltd.’s price is currently Overvalued.
Does Suraksha Diagnostic Ltd. pay dividends?
Suraksha Diagnostic Ltd. pays a N/A dividend of ₹0.5 which represents an annual dividend yield of N/A. See more information on Suraksha Diagnostic Ltd. dividends here
What is Suraksha Diagnostic Ltd.’s EPS estimate?
Suraksha Diagnostic Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Suraksha Diagnostic Ltd. have?
Suraksha Diagnostic Ltd. has 52,080,757 shares outstanding.
What happened to Suraksha Diagnostic Ltd.’s price movement after its last earnings report?
Suraksha Diagnostic Ltd. reported an EPS of ₹2.5 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 4.805%.
Which hedge fund is a major shareholder of Suraksha Diagnostic Ltd.?
Currently, no hedge funds are holding shares in IN:SURAKSHA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Suraksha Diagnostic Ltd.
Suraksha Diagnostic Limited operates a chain of diagnostic centers in India. It offers pathology testing services, such as microbiology, serology, molecular biology, histopathology, cytopathology, clinical pathology, and haematology; genomics testing, including microarray, noninvasive prenatal, quantitative fluorescent polymerase chain reaction, fluorescence in situ hybridization, and karyotyping; and radiology testing that includes X ray, magnetic resonance imaging, computed tomography scan, USG, DEXA scan, OPG, and mammography. The company also provides Cardiology testing services comprises electrocardiogram, echocardiogram, stress test / treadmill test, wireless holter monitoring, colour doppler, peripheral doppler, and pulmonary function test; gastroenterology, such as upper and lower GI endoscopy, sigmoidoscopy, proctoscopy, colonoscopy, and proctosigmoidoscopy; and neurology testing services, including electroencephalogram, electromyography, and nerve conduction velocity test. In addition, the company provides dental, physiotherapy, immunology & rheumatology, eye, fetal care, ENT, and speciality clinics, as well as home doctor visit services. The company was founded in 1992 and is based in Kolkata, India.
Technical Analysis
Krsnaa Diagnostics Limited
―
Dr. Lal PathLabs Limited
―
Metropolis Healthcare Ltd.
―
Thyrocare Technologies Ltd
―
Vimta Labs Limited
―